Curis, Inc.
(NASDAQ : CRIS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 6.84%170.810.0%$1433.85m
AMGNAmgen, Inc. 0.23%255.711.3%$690.21m
NVAXNovavax, Inc. 12.50%227.3580.0%$655.57m
SNSSSunesis Pharmaceuticals, Inc. -0.37%8.000.7%$559.23m
ILMNIllumina, Inc. -0.74%399.003.5%$519.65m
GILDGilead Sciences, Inc. 1.67%66.871.0%$470.50m
REGNRegeneron Pharmaceuticals, Inc. 1.61%502.602.7%$458.74m
VRTXVertex Pharmaceuticals, Inc. -0.77%219.391.9%$388.60m
ALXNAlexion Pharmaceuticals, Inc. 3.90%163.682.0%$348.10m
BNTXBioNTech SE 7.69%151.540.0%$313.57m
BIIBBiogen, Inc. -0.05%270.311.7%$263.29m
EXASEXACT Sciences Corp. -0.37%130.0418.4%$186.19m
NBIXNeurocrine Biosciences, Inc. 1.66%96.584.9%$179.73m
CRSPCRISPR Therapeutics AG -4.27%118.560.6%$166.57m
SGENSeagen Inc. -2.77%145.505.8%$146.84m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.